Volume 7 Supplement 6
Profiling of glycosylation gene expression in CHO fed-batch cultures in response to glycosylation-enhancing medium components
© Boniface et al; licensee BioMed Central Ltd. 2013
Published: 4 December 2013
Characterization of the glycosylation profile of a recombinant protein product is an important part of defining product quality in the bioproduction industry. Development of a protein with desired characteristics would require the capacity to modify and target specific glycosylation patterns as well as an understanding of the implications of changes to these glycosylation profiles. Previous cell culture studies have demonstrated the ability to modulate glycan profiles without negative impact to culture growth and product titer through the addition of glycosylation-enhancing medium components. With new methods, including increased measurement sensitivity and new capabilities in RNA-Seq technology, it is possible to develop a glycosylation gene expression profile for CHO cells. Specific glycosylation genes can then be tracked to ensure that the addition of these compounds will not negatively impact gene expression. Analyses comparing growth and titer, glycan distribution, and transcriptome differences can present us with potential insight into what changes are taking place on a genetic level in the cell in response to changes in medium and culture conditions.
Materials and methods
(All Materials were from Life Technologies unless otherwise indicated)
CHO-S® and DG44 derived recombinant cells expressing the same IgG molecule were grown in CD FortiCHO™ medium supplemented with 4mM L-glutamine and 1:100 Anti-Clumping Agent.
DASGIP bioreactor with 500mL initial working volume seeded at 0.3x105 viable cells/ml in CD FortiCHO™ medium. 10% CD EfficientFeed™ C (EFC) feeding on days 3, 5 and 7 for CHO-S® cultures, and feeding on days 4, 6 and 8 for DG44 cultures. Glucose concentration was maintained above 3g/L. Component A and/or component B were added on the first day of feeding (day 3 for CHO-S® and day 4 for DG44 cultures). Culture conditions were maintained as follows; pH 7.0 +/- 0.05, 50% DO, 37°C, 110 rpm. Cell densities and viabilities were measured using a Vi-CELL® counter (Beckman Coulter). Metabolites (glucose, ammonia, lactate) and IgG were measured using a Cedex® Bio HT Instrument (Roche).
Protein supernatant samples were collected and purified using POROS® MabCapture® A resin. Samples glycan profiles were analyzed on an Applied Biosystems® 3500 Series Genetic Analyzer.
RNA was extracted at several time points during the culture. A total of 174 potential glycosylation specific gene targets were identified and primers designed to these using reference sequences from Chinese hamster ovary, mouse, rat and human. A total of 34 samples were multiplexed on a Proton™ PI chip on the Ion Torrent™ PGM™.
Results and discussion
The comparison between CHO-S® and DG44 cultures without supplementation with components A or B revealed the DG44 culture had better galactosylation with increased proportions of G1F and G2F. Both cell lines express high levels of DDOST, RPN1, DAD1 and SST3A which are all part of the oligosaccharyltransferase complex which catalyzes the transfer of high mannose oligosaccharides from lipid-linked oligosaccharide donors to the asparagines on the Asn-X-Ser/Thr of the polypeptide chain. The DG44 cells differ from the CHO-S® cells with increases in: ALG2, ALG3, ALG9 and ALG12 (mannosyltransferases), ALG8 and ALG10 (glucosyltransferases), ALG14 (acetylglucosaminyltransferase), and B4GALT5 (galactosyltransferase). These increases in gene expression in DG44 cells seem to coincide with the higher galactosylation profiles observed in the glycan analysis.
Differences in growth, titer and glycoform distribution were observed between CHO-S® and CHO DG44 cells. DG44 cells had higher expression of glycosylation transferase genes compared to CHO-S® cells. Components A and B had synergistic effects on terminal galactosylation (Figure 1), showed no changes in gene expression and could be acting as cofactors/substrates with glycosylation enzymes.
The Austin team (Natalie Hernandez, Laura Chapman, Angie Cheng, Lea Kristi and Daniel Williams) for library preparation and transcriptome analysis.
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.